Zobrazeno 11 - 20
of 32
pro vyhledávání: '"J Thaddeus Beck"'
Autor:
Melinda L. Telli, Roohi Ismail-Khan, Chiun-Sheng Huang, Sherko Kümmel, Rafael López, Ingrid A. Mayer, J. Thaddeus Beck, Paloma Martín-Martorell, Marina Parton, Shin-Cheh Chen, Aditya Bardia, Daniel Carreon, Laura G. Estévez, Serena Liao, Scott Cameron, Sara A. Hurvitz, Manuel Ruiz-Borrego, Javier Cortes, José Baselga, Sung-Bae Kim
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Purpose There are currently no targeted therapies approved for triple-negative breast cancer (TNBC). A tumor necrosis factor α ( TNFα)–based gene expression signature (GS) predictive of sensitivity to LCL161, inhibitor of apoptosis antagonist, wa
Autor:
Nelly Failloux, J. Thaddeus Beck, Robert Daly, Ruth Pettengell, Donald Quick, Kai Hübel, James P Dean, Shaker R. Dakhil, Mariya Pavlyuk, Lowell F Inhorn, David Belada, Pencho Georgiev, David Andorsky
Publikováno v:
Future Oncology. 12:1759-1768
We describe the rationale and design of the ongoing randomized, active-controlled, multicenter, Phase III study evaluating the efficacy of pixantrone and rituximab versus gemcitabine and rituximab in patients with diffuse large B-cell lymphoma or fol
Autor:
Judith S. Kaur, Kathrin Strasser-Weippl, James N. Ingle, Julie R. Gralow, Keren Sturtz, Alison Stopeck, Kathleen I. Pritchard, Eric P. Winer, J. Thaddeus Beck, Wendy R. Parulekar, Sheldon Rubin, Karen A. Gelmon, Hyman B. Muss, Antonio C. Wolff, Clifford A. Hudis, Dongsheng Tu, Kate Whelan, Nicholas J. Robert, Paul E. Goss, Timothy J. Whelan
Publikováno v:
New England Journal of Medicine. 375:209-219
Canadian Cancer Society Research Institute [021039, 015469]; National Cancer Institute [CA180888, CA189953, CA180828, CA13612, CA37981, CA077202, CA180863, CA67753, CA189805, CA16116, CA180802]; Canadian Cancer Trials Group [CA077202, CA180863]; ECOG
Autor:
Andreas Schröder, Ramaswamy Govindan, Elizabeth E. Evans, Jonathan W. Goldman, John E. Leonard, Nagashree Seetharamu, Kevin M. Chin, Megan Ann Baumgart, Desa Rae Pastore, Yan Yan Lou, Rachel E. Sanborn, Aaron S. Mansfield, Nashat Y. Gabrail, Terrence L. Fisher, J. Thaddeus Beck, Ernest S. Smith, Maurice Zauderer, Alexander I. Spira, Crystal Mallow, Michael Shafique
Publikováno v:
Journal of Clinical Oncology. 38:75-75
75 Background: Despite progress of immune checkpoint therapies, many cases of non-small cell lung cancer (NSCLC) are refractory or acquire resistance to current therapies. Antibody blockade of semaphorin 4D (SEMA4D, CD100) can overcome resistance mec
Autor:
Judith Trotman, Sally F Barrington, David Belada, Michel Meignan, Robert MacEwan, Carolyn Owen, Václav Ptáčník, András Rosta, Günter R Fingerle-Rowson, Jiawen Zhu, Tina Nielsen, Deniz Sahin, Wolfgang Hiddemann, Robert E Marcus, Andrew Davies, Mark Hertzberg, Andrew Grigg, Paul Cannell, Hang Quach, Stephen Opat, Constantine Tam, Paula Marlton, Ann Janssens, Fritz Offner, Koen Van eygen, Randeep Sangha, Pam Mckay, Jonathan Wilson, Richard Van Der Jagt, Daryl Roitman, Marek Trneny, Jiri Mayer, Katell Le Du, Philippe Solal-Celigny, Guillaume Cartron, Charles Foussard, Norbert Frickhofen, Peter Schmidt, Ullrich Graeven, Tobias Gaska, Rudolf Schlag, Martin Sökler, Gabriele Prange-Krex, Axel Florschütz, Hans-Walter Lindemann, Christoph Schimmelpfennig, Solveig Tonndorf, Mathias Hänel, Georg Hess, Enrico Schalk, Heiko Hütten, Gottfried Doelken, Michael Pfreundschuh, Ulrich Keller, Michael Herold, Roswitha Forstpointner, Ursula Vehling-Kaiser, Martin Hoffmann, Zita Borbenyi, Miklos Udvardy, Judit Demeter, Alessandro Rambaldi, Enrica Morra, Federico Massimo, Ignazio Majolino, Monica Balzarotti, Gianpietro Semenzato, Miguel Angel Canales Albendea, Francisco Javier Peñalver Parraga, Alfonso Soler Campos, Juan Manuel Sancho Cia, Jose Antonio Marquez Navarro, Carlos Grande Garcia, Herman Nilsson-Ehle, Helen Mccarthy, Chris Pocock, Shalal Sadullah, Ram Malladi, John Radford, Ed Kanfer, Anton Kruger, Dominic Culligan, Martin Dyer, Ruth Pettengell, John Seymour, John Gribben, Saad Al-Ismail, Faris Al-Refaie, Norbert Blesing, Christopher Macnamara, Ann O'callaghan, Andrew Haynes, George Follows, Roderick Johnson, David Cunningham, Kristian Bowles, Graham Collins, Eve Gallop-Evans, Stephen Robinson, Chezhian Subash, James Bailey, Viran Holden, Jeffrey Neidhart, Moacyr De Oliveira, Haluk Tezcan, Kevin Kim, Suman Kambhampati, Keith Lanier, John Mcclean, Kensei Tobinai, Kiyohiko Hatake, Michinori Ogura, Toshiki Uchida, Kiyoshi Ando, Tomohiro Kinoshita, Thomas Höhler, Heribert Stauder, Andreas Kirsch, Michael Koenigsmann, Stephan Kremers, Thomas Illmer, Mathias Witzens-Harig, Paul La Roseé, Jan Dürig, Michael Kneba, Manfred Hensel, Stefan Fuxius, Lothar Bergmann, Kai Hübel, Christian Buske, Reinhard Marks, Gerald Wulf, Christian Lerchenmueller, Rudolf Schmits, Mark Reinwald, Eva Lengfelder, Fiona Scott, Takaaki Chou, Masafumi Taniwaki, Isao Yoshida, Kenichi Ishizawa, Naokuni Uike, Nobuhiko Uoshima, Yuri Kamitsuji, Shinsuke Iida, Ken Ohmine, Kisato Nosaka, Kazuhiko Ide, Takayuki Ishikawa, Pierre Desjardins, Nicholas Finn, Jun Zhu, Wei Li, Li Yu, Hanyun Ren, Yuan Kai Shi, Gang Wu, Xiaonan Hong, Qingyuan Zhang, Jifeng Feng, Rong Zhan, Tongyu Lin, Sirpa Leppa, Regis Costello, Adrian Tempescul, Laurence Sanhes, Olivier Tournilhac, Heinz Kirchen, Holger Hebart, Rudolf Weide, Kathleen Jentsch-Ullrich, Irit Avivi, Arnon Nagler, Ronit Gurion, Ofer Shpilberg, Pietro Leoni, Luca Baldini, Olga Samoylova, Alexandr Myasnikov, Tran-Der Tan, Hung Chang, Kyoya Kumagai, Norifumi Tsukamoto, Kunihiro Tsukasaki, Patrick Beatty, Noriko Usui, Koji Izutsu, Tohru Murayama, Tatsuo Ichinohe, Kohmei Kubo, Fumihiro Ishida, J. Thaddeus Beck, Frank Griesinger, Dzhelil Osmanov, Shaker Dakhil, Aline Clavert, Dai Maruyama, Yasuhito Terui, Kazuhito Yamamoto, Ekkehard Eigendorff, Tsutomu Kobayashi, Satoshi Ichikawa, Ilseung Choi, Katsuya Wada, Yoshitaka Kikukawa, Masao Matsuoka, Takayuki Yoshino, Yosuke Minami
Publikováno v:
Lancet Oncology
Lancet Oncology, Elsevier, 2018, 19 (11), pp.1530--1542. ⟨10.1016/S1470-2045(18)30618-1⟩
Trotman, J, Barrington, S F, Belada, D, Meignan, M, MacEwan, R, Owen, C, Ptáčník, V, Rosta, A, Fingerle-Rowson, G R, Zhu, J, Nielsen, T, Sahin, D, Hiddemann, W, Marcus, R E, Davies, A 2018, ' Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) : secondary analysis of a randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 11, pp. 1530-1542 . https://doi.org/10.1016/S1470-2045(18)30618-1
PET investigators from the GALLIUM study 2018, ' Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) : secondary analysis of a randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 11, pp. 1530-1542 . https://doi.org/10.1016/S1470-2045(18)30618-1
Lancet Oncology, Elsevier, 2018, 19 (11), pp.1530--1542. ⟨10.1016/S1470-2045(18)30618-1⟩
Trotman, J, Barrington, S F, Belada, D, Meignan, M, MacEwan, R, Owen, C, Ptáčník, V, Rosta, A, Fingerle-Rowson, G R, Zhu, J, Nielsen, T, Sahin, D, Hiddemann, W, Marcus, R E, Davies, A 2018, ' Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) : secondary analysis of a randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 11, pp. 1530-1542 . https://doi.org/10.1016/S1470-2045(18)30618-1
PET investigators from the GALLIUM study 2018, ' Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM) : secondary analysis of a randomised, phase 3 trial ', The Lancet Oncology, vol. 19, no. 11, pp. 1530-1542 . https://doi.org/10.1016/S1470-2045(18)30618-1
BACKGROUND: Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy with obinutuzumab than with rituximab. The aim of this secondary
Publikováno v:
Cancer treatment reviews. 69
Metastatic breast cancer (MBC) is the leading cause of cancer-related morbidity and mortality among women worldwide. Endocrine therapy is the standard of care for the most common subtype of MBC, hormone-receptor positive (HR+), human epidermal growth
Autor:
Weijiang Zhang, Christine McIntyre, Stjepko Pleština, J. Thaddeus Beck, Enric Bertran, Rabab Gaafar, Hanaa M.A. Kohail, Harper Forbes, Todd Riehl
Vemurafenib prolongs survival in patients with BRAFV600 -mutated advanced melanoma. In vitro studies show cytochrome P450 (CYP) 3A4 is involved in vemurafenib metabolism, but the effect of strong inducers or inhibitors of CYP3A4 on vemurafenib exposu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3dd281933c6918c3b94a3812fa26db7
https://doi.org/10.1002/cpdd.643
https://doi.org/10.1002/cpdd.643
Autor:
J. Thaddeus Beck, Lasika Seneviratne, Robert William Sweetman, John A. Glaspy, Navneet Dhillon, Chaitali Singh Nangia, Leon Christopher Hwang, Mark S. Chambers, Jennifer K. Litton, J. Randy Sabo, Hope S. Rugo, Timothy F. Meiller, Timothy J. Pluard, Julio A Peguero, Ingrid A. Mayer
Publikováno v:
The Lancet. Oncology. 18(5)
Summary Background Stomatitis is a class effect associated with the inhibition of mTOR and is associated with everolimus therapy for breast cancer. Topical steroids might reduce stomatitis incidence and severity, and the need for dose reductions and
Autor:
Kenneth M. Attie, Elizabeth R. Plimack, Rupal S. Bhatt, Brian I. Rini, Robert S. Alter, J. Thaddeus Beck, Shuchi Sumant Pandya, Matthew L. Sherman, Dawn Wilson, Musa Mutyaba, Xiaosha Zhang, Martin H. Voss, Michael B. Atkins, Chad E. Glasser
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(14)
Purpose: Activin receptor-like kinase 1 (ALK1) is a novel target in angiogenesis. Concurrent targeting of ALK1 and VEGF signaling results in augmented inhibition of tumor growth in renal cell carcinoma (RCC) xenograft models. Dalantercept is an ALK1-
Autor:
Zhao Yang, Rajesh K. Malik, Janakiraman Subramanian, Lowell L. Hart, Raid Aljumaily, David R. Spigel, Renata Ferrarotto, Misha L. Johnson, Wahid Hanna, Dragana Jovanovic, Z. Andric, Maen A. Hussein, Taofeek K. Owonikoko, Bojan Zaric, Krishna Kishore Pachipala, J. Thaddeus Beck, Shannon R. Morris, Steven Adler, Miroslav Samarzija, Davorin Radosavljevic
Publikováno v:
Journal of Clinical Oncology. 37:8505-8505
8505 Background: Multi-lineage myelosuppression is an acute toxicity of cytotoxic chemotherapy leading to hematologic adverse events and dose reductions and delays. Current therapies are lineage specific and administered after chemotherapy damage.Tri